Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company headquartered in Dallas, Texas. It focuses on advancing FB102, a proprietary anti-CD122 monoclonal antibody candidate targeting autoimmune and related indications such as vitiligo and celiac disease.
As of August 2026, the company is subject to a pending acquisition by argenx through a cash tender offer at $77 per share, representing an equity value of approximately $2.2 billion. The transaction, announced in July 2026 and expected to close in Q3 2026, remains subject to customary conditions including regulatory approvals.
None yet. When a new project in the record names Forte Biosciences as owner, partner or investor, it shows here.
FB102, a CD122 inhibitor, met the primary histology endpoint (Vh:Cd change; p=0.0176) versus placebo and showed aligned symptom and inflammatory benefits with no new safety signals.
Adds FB102, a first‑in‑class anti‑CD122 with clinical proof‑of‑concept in vitiligo and celiac disease; $77 per‑share tender offer completed and merger closed.
Commences cash offer of $77 per share; merger to follow subject to HSR clearance and a >50% tender condition.
FB102 shows Phase 1b proof in vitiligo and celiac; Phase 2 in celiac expected H2 2026. Acquisition executed as $77/share cash tender offer; close targeted Q3 2026.
